NEW YORK & WESTFIELD, N.J., June 29, 2026
Talawar Therapeutics has announced a definitive business combination agreement with JATT II Acquisition Corp. that will create a publicly listed biotechnology company focused on developing next-generation bispecific antibodies for immunology and inflammatory (I&I) diseases. The transaction is supported by an oversubscribed $225 million private investment in public equity (PIPE) and is expected to provide approximately $285 million in total cash at closing, subject to customary conditions and shareholder approvals. The financing is designed to accelerate the clinical development of TALA-125, Talawar’s lead anti-IL-13 × anti-IL-18 bispecific antibody for atopic dermatitis, with clinical entry anticipated in the first quarter of 2027 and a Phase 2b proof-of-concept data readout expected during the second half of 2028. Following completion of the transaction, the combined company will operate as Talawar Therapeutics and is expected to trade on the Nasdaq Capital Market under the ticker symbol TLWR, positioning the company to advance innovative immunology therapies for patients with significant unmet medical needs.
TALA-125 Designed to Advance Bispecific Immunology Therapies
TALA-125 represents Talawar’s lead investigational therapy and has been specifically engineered to overcome the limitations of current monotherapy treatments for atopic dermatitis, one of the largest therapeutic markets in inflammatory diseases. The novel bispecific antibody simultaneously targets IL-13 and IL-18, combining two clinically validated and complementary biological pathways within a single molecule to potentially deliver stronger and more durable therapeutic responses than existing single-target therapies. According to the company, many patients continue to experience inadequate disease control despite currently available treatments, creating an opportunity for innovative dual-target biologics capable of improving clinical outcomes.
Beyond TALA-125, Talawar is also expanding its immunology pipeline with additional discovery-stage candidates, including TALA-307 and TALA-711, reinforcing its strategy of developing best-in-class bispecific therapies that address multiple disease-driving mechanisms simultaneously. The company’s scientific platform, originally established through Khanda Therapeutics, focuses on pairing complementary biological pathways to maximize therapeutic efficacy across chronic inflammatory diseases.
Strong Financing and Leadership Support Long-Term Growth
Advertisement
The proposed business combination provides Talawar with substantial financial resources to execute its clinical development strategy while strengthening its position within the biotechnology sector. The $225 million PIPE financing attracted participation from several leading healthcare-focused institutional investors, demonstrating strong confidence in Talawar’s scientific platform and development strategy. Company leadership believes the funding will provide sufficient capital to advance TALA-125 through important clinical milestones while supporting continued pipeline expansion. Talawar is led by experienced biotechnology executives, including Chief Executive Officer Dr. Marc Schegerin and Chief Medical Officer Dr. Fabio Nunes, both of whom bring extensive expertise in pharmaceutical strategy and immunology drug development. The appointment of Dr. Praveen Tipirneni to the company’s Board of Directors further strengthens its leadership with significant biotechnology commercialization experience.
The merger represents an important milestone for Talawar, enabling the company to access public capital markets while accelerating innovation in inflammatory disease treatment through advanced bispecific antibody technologies. As demand continues to grow for more effective biologic therapies capable of delivering improved clinical outcomes, Talawar Therapeutics is positioning itself as an emerging biotechnology company focused on redefining treatment options for patients living with chronic immunology and inflammatory disorders, supported by strong financial backing, experienced leadership, and a differentiated scientific platform capable of addressing significant unmet medical needs.
Source: Talawar Therapeutics press release
